Back to top

Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial

Mesoblast (MESO) announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Mesoblast Limited (MESO)